Mackenzie Financial Corp purchased a new stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,023 shares of the company's stock, valued at approximately $276,000.
Several other large investors have also made changes to their positions in MD. Parkside Financial Bank & Trust increased its position in Pediatrix Medical Group by 36.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,919 shares of the company's stock worth $51,000 after buying an additional 1,040 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its holdings in shares of Pediatrix Medical Group by 95.3% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 2,500 shares of the company's stock valued at $33,000 after acquiring an additional 1,220 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Pediatrix Medical Group by 65.9% in the 4th quarter. AlphaQuest LLC now owns 5,066 shares of the company's stock valued at $66,000 after acquiring an additional 2,012 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Pediatrix Medical Group by 6.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,002 shares of the company's stock valued at $643,000 after acquiring an additional 2,801 shares in the last quarter. Finally, Illinois Municipal Retirement Fund lifted its holdings in Pediatrix Medical Group by 7.8% in the 4th quarter. Illinois Municipal Retirement Fund now owns 47,409 shares of the company's stock worth $622,000 after purchasing an additional 3,411 shares during the last quarter. Institutional investors own 97.71% of the company's stock.
Analysts Set New Price Targets
MD has been the topic of several analyst reports. Macquarie increased their price target on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. UBS Group lowered their target price on shares of Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating on the stock in a research note on Monday, May 12th. Finally, Truist Financial dropped their target price on shares of Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $16.67.
Check Out Our Latest Report on Pediatrix Medical Group
Pediatrix Medical Group Stock Performance
MD traded up $0.19 on Friday, hitting $14.11. 771,894 shares of the stock traded hands, compared to its average volume of 826,578. The business has a fifty day moving average price of $13.65 and a two-hundred day moving average price of $14.00. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $1.21 billion, a PE ratio of -11.76, a P/E/G ratio of 1.74 and a beta of 1.27. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $17.67.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.08. The business had revenue of $458.36 million for the quarter, compared to analysts' expectations of $451.44 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. Pediatrix Medical Group's quarterly revenue was down 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.20 earnings per share. On average, research analysts predict that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.
Pediatrix Medical Group Company Profile
(
Free Report)
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Further Reading

Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.